| abstract |
Metabolites of 2- (R) -4-isobutylarylpropionamide and pharmaceutical compositions containing such compounds are induced by the interaction of interleukin 8 (IL-8) with CXCR1 and CXCR2 membrane receptors It is useful for inhibiting the chemotactic activation of neutrophils (PMN leukocytes). This compound is used for prevention and treatment of a disease state resulting from the activation. In particular, these metabolites lack cyclooxygenase inhibitory activity and include psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, thread It is particularly useful for the treatment of neutrophil dependent conditions such as glomerulonephritis and for the prevention and treatment of ischemia-reperfusion injury. |